Global Regulators Issue Advice On Clinical Comparability Of Biosimilar MAbs
Executive Summary
The International Pharmaceutical Regulators Programme has documented various approaches currently being used for the clinical comparability of biosimilar monoclonal antibodies in different jurisdictions.